Results 191 to 200 of about 311,440 (293)

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, EarlyView.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

A report of novel inactivating missense mutations of BRCA1 detected in patients with acute myeloid leukemia. [PDF]

J Med Case Rep
Ejaz S, Raashid A, Hameed Y, Abdullah I, Imtiaz N, Iqbal M, Khurshid M, Malik WN.   +7 more
europepmc   +1 more source

Association of Childhood Acute Leukemia With Autoimmune Diseases

International Journal of Cancer, EarlyView.
A possible link exists between various pediatric autoimmune diseases (AIDs) and increased risk of childhood leukemia. Although immune dysregulation is a key feature of these conditions, the connection between them remains unclear. In this study, using cancer registry data in Finland, the authors examined associations between AIDs and childhood acute ...
Ida Pellikka, Julia Ventelä, Anssi Auvinen, Olli Lohi, Atte Nikkilä   +4 more
wiley   +1 more source

Selinexor and Venetoclax Combination in Patients With Relapsed or Refractory Acute Myeloid Leukemia. [PDF]

Am J Hematol
Ball S, Awan FT, Tomlinson BK, Stopczynski T, Fischer MA, Zhao Z, Fedorov K, Kishtagari A, Mohan SR, Ayers GD, Byrne MT, Savona MR.   +11 more
europepmc   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Clinico-genomic characterization of RAS-mutant acute myeloid leukemia. [PDF]

Ann Hematol
Yuan R, Xie Y, Miron PM, Higgins AW, Hutchinson L, Cerny J, Patel SA.   +6 more
europepmc   +1 more source

Adverse Health Events in Chronic Myeloid Leukaemia Patients Treated With Tyrosine Kinase Inhibitors 2009–2019: A Real‐World Study From the UK's Haematological Malignancy Research Network

International Journal of Cancer, EarlyView.
Although tyrosine kinase inhibitors (TKIs) improve chronic myeloid leukemia (CML) outcome, long‐term effects remain unclear, particularly in real‐world settings. Here, the authors examined morbidity and mortality in CML patients treated with TKIs between 2009 and 2019 in the United Kingdom.
Eleanor Kane, Alexandra Smith, Debra Howell, Catherine Cargo, Kate Rothwell, Simone Green, Russell Patmore, Eve Roman   +7 more
wiley   +1 more source

Assessing the contributions of noncoding RNAs in acute myeloid leukemia. [PDF]

Blood Neoplasia
Zakutansky PM, Boucher AC, Crispino JD.
europepmc   +1 more source

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Combination of Lenvatinib and Antibiotics: A Potential Approach to Enhance Sensitivity in Differentiated Thyroid Cancer

International Journal of Cancer, EarlyView.
Although lenvatinib is the current first‐line therapy for radioiodine‐refractory differentiated thyroid carcinoma, its use is limited by severe side effects and reduced sensitivity. Here, the authors assessed the potential of sensitizing differentiated thyroid carcinoma tumor cells with limited lenvatinib responsiveness through the administration of ...
Celina Ablinger, Petra Huber‐Cantonati, Daniela D. Weber, Sarah Pichler, Georg Schischkow, Marta Garcia‐Miralles, Christian Pirich, Gundula Rendl, Teresa Kiener, Thomas Felder, Martin Geroldinger, Robert Terkola, Barbara Kofler, Johanna Pachmayr   +13 more
wiley   +1 more source